A gene that kills the mosquitoes spreading dengue was engineered two decades ago, but it has spent fifteen years bouncing between three US agencies and still isn't approved.
Americans think of malaria and dengue as other people's problems. That was mostly true until recently. In 2024 the US reported nearly 4,000 dengue cases, more than seven times the previous decade's average, and Puerto Rico declared a public health emergency.
A gene that ends the family line
Scientists at Oxford inserted a gene into male mosquitoes so their offspring never reach adulthood. The team formed a company, Oxitec, and moved the gene into Aedes aegypti, the mosquito that spreads dengue. It kills only the female offspring; the males survive and pass the gene on.
The results were stark: an 80% cut in wild mosquito numbers in the Cayman Islands, about 95% at a trial site in Brazil. In 2010 the company submitted its data seeking US approval.
Three agencies, none of them wants it
First the Department of Agriculture, which took eighteen months to reply that it wasn't their call and the company should try the Food and Drug Administration. The FDA's reasoning: altered DNA in an animal counts as a drug. That fit a mosquito about as well as a shoe fits a fish, and five more years went by.
The conclusion was that the Environmental Protection Agency should handle it, since mosquitoes count as pesticides. In 2020, a decade after the original application, the EPA finally issued a permit to run trials — but not to sell anything.
In 2022 the trials were extended to California, clearing up to 2.4 billion mosquitoes for release. Public pushback paused them. The permit expired in April 2024, and full commercial registration is still pending. A review meeting set for November 2025 was postponed with no new date.
A different approach gets through
Another route skips genetic modification entirely. A bacterium called Wolbachia naturally infects about 60% of insect species. Mosquitoes carrying it struggle to carry dengue, and pass the protection to their offspring.
Because it isn't genetic engineering, it sidesteps most of what stalled Oxitec. In a randomised trial in Singapore, releasing infected males cut mosquito numbers by 85% and dengue infections by roughly 70%. In 2024 MosquitoMate became the first company with full nationwide registration, and California and Florida are already using it.
The real problem isn't the science. It's staffing. Two thirds of the FDA's drug review budget comes from industry fees, and new drug review times fell from 29 months to under 10. The EPA gets two thirds of its money from Congress, so it queues.
In one line: whether you get bitten now depends on when your form reaches the top of the pile.
Why it matters
This isn't really about mosquitoes. It's about the gate every new technology has to pass: one agency takes eighteen months to say you knocked on the wrong door, another takes five years to admit its rules don't fit — and behind each review, real case numbers keep climbing.
Curated from high-quality sources, with concise summaries and key takeaways.
